Published in Oncotarget on August 28, 2015
A Study of LY2157299 in Participants With Hepatocellular Carcinoma | NCT01246986
Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol (2016) 0.83
Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget (2016) 0.78
Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes. Sci Rep (2016) 0.76
A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis. Am J Blood Res (2015) 0.76
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res (2016) 0.75
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Int J Mol Sci (2017) 0.75
Pharmacological and immunological targeting of tumor mesenchymalization. Pharmacol Ther (2016) 0.75
De Novo Emergence of Mesenchymal Stem-Like CD105(+) Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma. Transl Oncol (2017) 0.75
Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. Br J Pharmacol (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov (2004) 3.47
Non-Smad signaling pathways. Cell Tissue Res (2011) 2.52
Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49
Genetics of hepatocellular tumors. Oncogene (2006) 2.43
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology (2013) 1.87
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology (2008) 1.73
Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res (2014) 1.49
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (1995) 1.41
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology (2009) 1.27
Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene (1999) 1.21
Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta (2010) 1.20
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol (2014) 1.16
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II. PLoS One (2013) 1.06
Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest (2010) 1.04
Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling. Oncol Lett (2012) 0.96
Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int J Cancer (1999) 0.93
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol (2010) 0.93
Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines. PLoS One (2013) 0.92
Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. Ann Surg Oncol (2009) 0.91
Smad4 expression in hepatocellular carcinoma differs by hepatitis status. Asian Pac J Cancer Prev (2012) 0.81
Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. Hum Pathol (2002) 0.81